You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The companies discussed their plans to change the one-test, one-drug companion diagnostic paradigm at the Personalized and Precision Medicine conference this week.
The national provider agreement is the latest in a series of deals related to reimbursement for the firm's genetic tests.
The company is in the beginning stages of product development, but is confident that it has a product that will be successful in the early diagnostics market.
Under the agreement, Precipio would become a wholly owned subsidiary of Transgenomic, which would then adopt the new name Precipio.
Multiple variant databases are creating competition among groups that disagree on how to advance the most scientifically robust and sustainable sharing model.
A Counsyl study suggests that just half of individuals go through with insurance-mandated pretest genetic counseling, paying out of pocket or canceling the test instead.
The companies will initially focus on developing a companion diagnostic for Merck's investigational B cell lymphoma drug M7583.
Experts said that the EMR is a crucial channel for aggregating clinical insights from multiple sources, but plenty of work is needed to achieve broader adoption.
The model could shift which patients receive gene expression profiling assays but might not change the number of tests ordered.
The study showed an overall benefit regardless of BRCA mutation or HRD status, but some analysts believe the FDA still might require a CDx for niraparib.
Although Tesaro used Myriad's BRCA and HRD tests to stratify patients, in the NOVA trial all recurrent ovarian cancer patients benefitted from niraparib.
Scientists at Memorial Sloan Kettering Cancer Center, led by Gabriela Chiosis, revealed how the complexes are important for tumor survival in certain cases.
Experts at CAP16 said most practicing pathologists operate within specialties and rarely cross the divide into other test disciplines, which thwarts optimal patient care.
The project team is driving the development of practice guidelines because sample handling and quality are often not up to the mark.
The Xpert Bladder Cancer Monitor test for the GeneXpert system has a high negative predictive value and provides results non-invasively in about 90 minutes.
The positive insurance coverage decision for ConfirmMDx is one of several the company has received in recent months.
The state has given its approval for the company to market its ThyGenX next-generation sequencing oncogene panel for indeterminate thyroid nodules.
Cambridge Bioscience will exclusively distribute the Xcell platform in the UK and BioStream will disburse the system in Japan.
The investment bank said NeoGenomics and its clients are likely to benefit from a product portfolio expanded by the acquisition of Clarient.
The partners will provide testing through a program through which they also plan to establish a database of genetic test results and patient outcomes.